Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

[1]  A. Ullrich,et al.  Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. , 1991, Growth regulation.

[2]  J. Berek,et al.  Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. , 1990, Cancer research.

[3]  R. Lupu,et al.  Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. , 1990, Science.

[4]  D. Weiner,et al.  p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.

[5]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[6]  S. Szala,et al.  Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[8]  A. Ullrich,et al.  Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.

[9]  S. Larson,et al.  Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. , 1990, Cancer research.

[10]  T. Yagi,et al.  Induction of a variety of tumors by c‐erbB2 and clonal nature of lymphomas even with the mutated gene (Val659‐‐‐‐Glu659). , 1990, The EMBO journal.

[11]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[12]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[13]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[14]  M. Sela,et al.  Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. , 1988, Journal of the National Cancer Institute.

[15]  H. Shepard,et al.  Resistance of tumor cells to tumor necrosis factor , 1988, Journal of Clinical Immunology.

[16]  A. Ullrich,et al.  Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[18]  A. Ullrich,et al.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[20]  G. Nicolson,et al.  Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. , 1987, Cancer research.

[21]  J. Bishop.  The molecular genetics of cancer. , 1987, Science.

[22]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[23]  H. Shepard,et al.  Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Cori Bargmann,et al.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.

[25]  P. Nowell.  Mechanisms of tumor progression. , 1986, Cancer research.

[26]  Robert A. Weinberg,et al.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies , 1985, Cell.

[27]  R. Weinberg,et al.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.

[28]  J. Mendelsohn,et al.  Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. , 1984, The Journal of biological chemistry.

[29]  R. Weinberg,et al.  Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas , 1982, Cell.

[30]  M. Kaliner,et al.  Late-phase IgE-mediated reactions , 2004, Journal of Clinical Immunology.

[31]  C R King,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Mendelsohn,et al.  Anti-EGF receptor monoclonal antibodies: biological studies and potential clinical applications. , 1989, Transactions of the American Clinical and Climatological Association.

[33]  A. Ullrich,et al.  Growth factor receptor tyrosine kinases. , 1988, Annual review of biochemistry.

[34]  Rhim Js.  Viruses, oncogenes, and cancer. , 1988 .